PODD

Business Context and Reporting Period

Company: Insulet Corporation (NASDAQ: PODD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Insulet is a medical device company developing, manufacturing, and marketing the OmniPod Insulin Management System, a tubeless, wearable insulin infusion system for insulin-dependent diabetes. The company commercially launched the system in October 2005. As of December 31, 2007, the company had 247 full-time employees and operates primarily from facilities in Bedford and Billerica, Massachusetts.

Key Financial Metrics

Note: The company incurred a gross loss in 2007 because the sale price of the OmniPod System did not cover direct manufacturing costs. Inventory was written down to the lower of cost or market, increasing cost of revenue by $625,000.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 265% to $13.4 million, driven by an increase in the number of customers using the OmniPod system.
• Expense Increases:
  • Sales and Marketing: Increased 162% to $16.1 million due to hiring additional personnel, patient demonstration kits, and travel expenses.
  • General and Administrative: Increased 66% to $13.9 million, largely due to employee-related expenses, allowances for doubtful accounts ($971,000), and audit/legal fees.
  • Research and Development: Increased 28% to $10.4 million.
• Asset Impairment: Recorded a non-cash charge of $1.0 million for the write-down of manufacturing equipment with no future use.
• Liquidity Position: Cash and cash equivalents grew significantly from $33.2 million to $94.6 million, primarily due to net proceeds of $113.4 million from the Initial Public Offering (IPO) in May 2007 and $9.2 million from a secondary offering in November 2007.
• Debt Structure: The company repaid a $10 million loan from Lighthouse Capital Partners in December 2006 using proceeds from a new $30 million term loan with a group of lenders led by Merrill Lynch Capital. As of year-end, $10.7 million of this debt was classified as current and $16.0 million as long-term.

Outlook, Risks, and Management Commentary

• Profitability Path: Management states that the company will continue to incur net losses in the near term. Profitability depends on reducing per-unit production costs through the automation of manufacturing lines in Bedford, MA, and the completion of a new manufacturing line in China (operated by Flextronics) expected in 2008. Capacity is expected to increase from 60,000 units/month to over 200,000 units/month by late 2008.
• Reimbursement: The company relies on third-party payors for reimbursement. While contracts cover an estimated 146 million lives, Medicare coding verification is currently considered inappropriate for the OmniPod System, leading the company to focus on private insurers.
• Key Risks:
  • Manufacturing: Failure to automate production or secure supply from Flextronics could prevent cost reductions and profitability.
  • Competition: Intense competition from larger, well-capitalized companies (e.g., Medtronic, Animas, Deltec) with established market share.
  • Intellectual Property: Potential infringement claims, including a letter from Medtronic regarding patent licensing, though Insulet believes it has meritorious defenses.
  • Regulatory: Extensive FDA regulation; failure to comply could result in sanctions or production shutdowns.
• Subsequent Event: On March 3, 2008, the company amended its license agreement with Abbott Diabetes Care, extending the term to 2013 and expanding the license to Israel in exchange for exclusivity and ongoing payments.

Investor Verification Checklist

• Manufacturing Automation: Verify the timeline and success of the Bedford automation and the Flextronics China facility construction to confirm the ability to reduce cost of goods sold.
• Reimbursement Contracts: Monitor the status of Medicare coding verification and the renewal rates of private insurance contracts.
• Customer Retention: Assess customer retention rates and the conversion of patient referrals to actual sales.
• Intellectual Property Litigation: Track any developments regarding the Medtronic patent inquiry or other IP disputes.
• Cash Burn Rate: Monitor quarterly cash usage against the $94.6 million cash balance to ensure sufficiency for operations through the planned expansion phase.